Cardiovascular safety of empagliflozin in patients with Type 2 diabetes: a metaanalysis of placebo-controlled trials

被引：0
|
作者：
Salsali, A. [1 ]
Kim, G. [2 ]
Woerle, H. J. [2 ]
Broedl, U. C. [2 ]
Hantel, S. [3 ]
机构：
[1] Boehringer Ingelheim Pharmaceut Inc, Diabet Clin Res, 90 E Ridge POB 368, Ridgefield, CT 06877 USA
[2] Boehringer Ingelheim Pharma GmbH & Co KG, Med IA Metab, Ingelheim, Germany
[3] Boehringer Ingelheim Pharma GmbH & Co KG, Biostat & Data Sci, Biberach, Germany
来源：
DIABETIC MEDICINE | 2017年 / 34卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
A74
引用
收藏
页码：32 / 32
页数：1
相关论文
共 50 条
  • [31] Renal effects of empagliflozin alone or in combination with semaglutide in albuminuric type 2 diabetes: a randomised, placebo-controlled trial
    Sivalingam, S.
    Wasehuus, V. Soendergaard
    Curovic, V. Rotbain
    Hansen, T. Willum
    Persson, F.
    Rossing, P.
    DIABETOLOGIA, 2023, 66 (SUPPL 1) : S125 - S125
  • [32] Effect of Empagliflozin on Endothelial Function in Patients With Type 2 Diabetes and Cardiovascular Disease: Results from the Multicenter, Randomized, Placebo-Controlled, Double-Blind EMBLEM Trial
    Tanaka, Atsushi
    Shimabukuro, Michio
    Machii, Noritaka
    Teragawa, Hiroki
    Okada, Yosuke
    Shima, Kosuke R.
    Takamura, Toshinari
    Taguchi, Isao
    Hisauchi, Itaru
    Toyoda, Shigeru
    Matsuzawa, Yasushi
    Tomiyama, Hirofumi
    Yamaoka-Tojo, Minako
    Yoshida, Hisako
    Sato, Yasunori
    Ikehara, Yumi
    Ueda, Shinichiro
    Higashi, Yukihito
    Node, Koichi
    DIABETES CARE, 2019, 42 (10) : E159 - E161
  • [33] Cardiovascular safety of vardenafil in patients on antihypertensives and/or alpha-blockers: Analysis of 17 placebo-controlled trials
    White, WB
    Hellstrom, W
    Norenberg, C
    Porst, H
    JOURNAL OF SEX RESEARCH, 2006, 43 (01) : 29 - 30
  • [34] Safety and Tolerability of Empagliflozin in Patients with T2D and Advanced Kidney Disease: A Large, Pooled Analysis of Placebo-Controlled Clinical Trials
    Levin, Adeera
    Nangaku, Masaomi
    Kadowaki, Takashi
    Tuttle, Katherine R.
    Hauske, Sibylle Jenny
    Zeller, Cordula
    Kohler, Sven
    Von Eynatten, Maximilian
    Wanner, Christoph
    DIABETES, 2017, 66 : A325 - A325
  • [35] Safety and Tolerability of Combinations of Empagliflozin and Linagliptin in Patients with Type 2 Diabetes: Pooled Data from Two Randomized Controlled Trials
    Ralph A. DeFronzo
    Christopher Lee
    Sven Kohler
    Advances in Therapy, 2018, 35 : 1009 - 1022
  • [36] Safety and Tolerability of Combinations of Empagliflozin and Linagliptin in Patients with Type 2 Diabetes: Pooled Data from Two Randomized Controlled Trials
    DeFronzo, Ralph A.
    Lee, Christopher
    Kohler, Sven
    ADVANCES IN THERAPY, 2018, 35 (07) : 1009 - 1022
  • [37] METAANALYSIS OF DOUBLE-BLIND PLACEBO-CONTROLLED TRIALS OF ANTIDEPRESSANTS AND BENZODIAZEPINES FOR PATIENTS WITH PANIC DISORDERS
    WILKINSON, G
    BALESTRIERI, M
    RUGGERI, M
    BELLANTUONO, C
    PSYCHOLOGICAL MEDICINE, 1991, 21 (04) : 991 - 998
  • [38] Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial
    Barnett, Anthony H.
    Mithal, Ambrish
    Manassie, Jenny
    Jones, Russell
    Rattunde, Henning
    Woerle, Hans J.
    Broedl, Uli C.
    LANCET DIABETES & ENDOCRINOLOGY, 2014, 2 (05): : 369 - 384
  • [39] Secondary analyses to assess the profound effects of empagliflozin on endothelial function in patients with type 2 diabetes and established cardiovascular diseases: The placebo-controlled double-blind randomized effect of empagliflozin on endothelial function in cardiovascular high risk diabetes mellitus: Multi-center placebo-controlled double-blind randomized trial
    Tanaka, Atsushi
    Shimabukuro, Michio
    Machii, Noritaka
    Teragawa, Hiroki
    Okada, Yosuke
    Shima, Kosuke R.
    Takamura, Toshinari
    Taguchi, Isao
    Hisauchi, Itaru
    Toyoda, Shigeru
    Matsuzawa, Yasushi
    Tomiyama, Hirofumi
    Yamaoka-Tojo, Minako
    Ueda, Shinichiro
    Higashi, Yukihito
    Node, Koichi
    JOURNAL OF DIABETES INVESTIGATION, 2020, 11 (06) : 1551 - 1563
  • [40] Safety and tolerability of exenatide twice daily in patients with type 2 diabetes: integrated analysis of 5594 patients from 19 placebo-controlled and comparator-controlled clinical trials
    MacConell, Leigh
    Brown, Carl
    Gurney, Kate
    Han, Jenny
    DIABETES METABOLIC SYNDROME AND OBESITY-TARGETS AND THERAPY, 2012, 5 : 29 - 41
12345